机构名称：
¥ 24.0
5。该患者已被记录为具有可起诉突变的NSCLC：EGFR 19或21，EGFR外显子20，ALK，ROS1，ROS1，RET，KRAS G12C，MET14。Please mark in the box below whether such an actionable mutation has been found or not: - only testing for an EGFR 19 or 21 mutation has been done and the result is negative - genomic testing has not been done for all the genomic alterations listed below and results so far have been negative - the patient's NSCLC is positive for an EGFR 19 or 21 mutation - the patient's NSCLC is positive for an EGFR exon 20 mutation - the patient's NSCLC is positive for a ALK gene fusion - the patient's NSCLC is positive for a ROS1 gene rearrangement - the patient's NSCLC is positive for a RET gene fusion - the patient's NSCLC is positive for a KRAS G12C mutation - the patient's NSCLC is positive for a MET exon 14 skipping mutation
国家癌症药物基金列表Ver1.333 20-Nov-24
主要关键词
相关文件推荐
